KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Net Margin (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Net Margin for 16 consecutive years, with 13.01% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin rose 2069.0% year-over-year to 13.01%, compared with a TTM value of 8.19% through Sep 2025, down 3260.0%, and an annual FY2024 reading of 7.44%, up 20552.0% over the prior year.
  • Net Margin was 13.01% for Q3 2025 at TherapeuticsMD, up from 0.63% in the prior quarter.
  • Across five years, Net Margin topped out at 36538.51% in Q2 2022 and bottomed at 4481.44% in Q1 2022.
  • Average Net Margin over 5 years is 1318.18%, with a median of 6.0% recorded in 2024.
  • Peak annual rise in Net Margin hit 3672394bps in 2022, while the deepest fall reached -428320bps in 2022.
  • Year by year, Net Margin stood at 65.39% in 2021, then crashed by -35bps to 42.66% in 2022, then skyrocketed by 207bps to 131.08% in 2023, then plummeted by -84bps to 20.69% in 2024, then crashed by -37bps to 13.01% in 2025.
  • Business Quant data shows Net Margin for TXMD at 13.01% in Q3 2025, 0.63% in Q2 2025, and 4.33% in Q1 2025.